Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SGYP
Previous Symbol
CUSIP87163930
Phone212-297-0020
Debt
Debt-to-Equity RatioN/A
Current Ratio2.83
Quick Ratio2.31
Price-To-Earnings
Trailing P/E Ratio-0.37
Forward P/E Ratio-0.70
P/E GrowthN/A
Sales & Book Value
Annual Sales$16.82 million
Price / Sales5.60
Cash FlowN/A
Price / CashN/A
Book Value($0.02) per share
Price / Book-19.00
Profitability
EPS (Most Recent Fiscal Year)($1.02)
Net Income$-224,330,000.00
Net Margins-332.11%
Return on EquityN/A
Return on Assets-107.19%
Miscellaneous
Employees313
Outstanding Shares247,990,000
Market Cap$88.66 million
OptionableOptionable
Synergy Pharmaceuticals (NASDAQ:SGYP) Frequently Asked Questions
What is Synergy Pharmaceuticals' stock symbol?
Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."
How were Synergy Pharmaceuticals' earnings last quarter?
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) released its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.01. The biopharmaceutical company had revenue of $11.11 million for the quarter, compared to analysts' expectations of $15.65 million. View Synergy Pharmaceuticals' Earnings History.
When is Synergy Pharmaceuticals' next earnings date?
What price target have analysts set for SGYP?
7 brokers have issued 12-month price targets for Synergy Pharmaceuticals' stock. Their predictions range from $7.00 to $13.00. On average, they anticipate Synergy Pharmaceuticals' stock price to reach $9.40 in the next twelve months. This suggests a possible upside of 2,373.7% from the stock's current price. View Analyst Price Targets for Synergy Pharmaceuticals.
What is the consensus analysts' recommendation for Synergy Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synergy Pharmaceuticals in the last year. There are currently 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Synergy Pharmaceuticals.
Has Synergy Pharmaceuticals been receiving favorable news coverage?
News coverage about SGYP stock has trended negative recently, according to InfoTrie. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Synergy Pharmaceuticals earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an effect on the stock's share price in the near future.
Are investors shorting Synergy Pharmaceuticals?
Synergy Pharmaceuticals saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 50,907,833 shares, a decrease of 15.7% from the October 15th total of 60,353,927 shares. Based on an average daily volume of 9,827,463 shares, the short-interest ratio is presently 5.2 days. Approximately 20.6% of the company's stock are short sold. View Synergy Pharmaceuticals' Current Options Chain.
Who are some of Synergy Pharmaceuticals' key competitors?
Some companies that are related to Synergy Pharmaceuticals include American Brivision (Holding) (ABVC), Seres Therapeutics (MCRB), Aclaris Therapeutics (ACRS), Adamas Pharmaceuticals (ADMS), TapImmune (MRKR), Aratana Therapeutics (PETX), Kalvista Pharmaceuticals (KALV), resTORbio (TORC), Merus (MRUS), Albireo Pharma (ALBO), Verrica Pharmaceuticals (VRCA), Geron (GERN), Kadmon (KDMN), Catalyst Pharmaceuticals (CPRX) and MannKind (MNKD).
Who are Synergy Pharmaceuticals' key executives?
Synergy Pharmaceuticals' management team includes the folowing people:
- Dr. Gary S. Jacob, Exec. Chairman (Age 71)
- Mr. Troy Hamilton Pharm.D., CEO & Director (Age 46)
- Mr. Gary G. Gemignani, Exec. VP & CFO (Age 53)
- Dr. Patrick H. Griffin, Exec. VP & Chief Medical Officer (Age 63)
- Gem Gokmen Hopkins, VP of Investor Relations and Corp. Communications
Who are Synergy Pharmaceuticals' major shareholders?
Synergy Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.99%), Hikari Power Ltd (1.01%) and Chicago Equity Partners LLC (0.19%). Company insiders that own Synergy Pharmaceuticals stock include Gary S Jacob, John P Brancaccio and Paulson & Co Inc. View Institutional Ownership Trends for Synergy Pharmaceuticals.
Which major investors are buying Synergy Pharmaceuticals stock?
SGYP stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Chicago Equity Partners LLC and Hikari Power Ltd. Company insiders that have bought Synergy Pharmaceuticals stock in the last two years include Gary S Jacob and John P Brancaccio. View Insider Buying and Selling for Synergy Pharmaceuticals.
How do I buy shares of Synergy Pharmaceuticals?
Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synergy Pharmaceuticals' stock price today?
One share of SGYP stock can currently be purchased for approximately $0.38.
How big of a company is Synergy Pharmaceuticals?
Synergy Pharmaceuticals has a market capitalization of $88.66 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.
What is Synergy Pharmaceuticals' official website?
How can I contact Synergy Pharmaceuticals?
Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]
MarketBeat Community Rating for Synergy Pharmaceuticals (NASDAQ SGYP)
MarketBeat's community ratings are surveys of what our community members think about Synergy Pharmaceuticals and other stocks. Vote "Outperform" if you believe SGYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGYP will underperform the S&P 500 over the long term. You may vote once every thirty days.
